Last reviewed · How we verify
NCT02040220: JPMS-CRVO
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)
trial testing Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) in Retinal Vein Occlusion in 385 participants. Completed in 9 November 2018.
1 June 2018
Quick facts
| Lead sponsor | Bayer |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 385 |
| Start date | 24 January 2014 |
| Primary completion | 1 June 2018 |
| Estimated completion | 9 November 2018 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) — full drug profile →
Conditions studied
- Retinal Vein Occlusion — all drugs for Retinal Vein Occlusion →
Sponsor
Bayer — full company profile →
Who can join
Eligibility, any sex, with Retinal Vein Occlusion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, non-interventional, multi center post-authorization safety study that includes patients with a diagnosis of CRVO. The investigator will have made the choice of treatment (EYLEA) as well as the decision to use EYLEA according the Japanese Package Insert prior to enrolling the patient in this study. The observation period for each patient starts when therapy with EYLEA is initiated. The enrollment period is 2 years. Patients will be followed for a time period of 2 years or until it is no longer possible (e.g. lost to follow-up) within the 2 years. For each patient, data are collected as defined in the case report form at the initial visit, follow-up visits and final visit, either by routine clinical visits (as per investigators routine practice). There will interim analysis of study data: 6 months after last patient first visit and J-PSUR(Japanese-Periodic Safety Update Report )
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Real-World Data on Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 24-Month Outcomes.
Shimura M, Fukumatsu M, Tsujimura J, Hirano K, et al · · 2022 · cited 6× · PMID 35256840 · DOI 10.2147/opth.s344194
Verify or expand the search:
- PubMed search for NCT02040220
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Trials testing the same drug.
- NCT05511038 — A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participant · Phase 4 · completed
- NCT04524910 — A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vess · completed
- NCT04641234 — A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-relat · completed
- NCT02818998 — Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME) · Phase 3 · completed
- NCT02811692 — Study for Collection of Aflibercept Data in Routine Practice · completed
Other recruiting trials for Retinal Vein Occlusion
Currently open trials in the same condition.
- NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
- NCT06439576 — Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Relat · recruiting
- NCT07106268 — Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema · active not recruiting
- NCT05476926 — A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products · active not recruiting
- NCT04505618 — Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease · NA · recruiting
Other Bayer trials
Trials by the same sponsor.
- NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
- NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
- NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02040220 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bayer
- Last refreshed: 10 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02040220.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing